Local media: UC, UC Health to examine potential COVID-19 treatment
In the absence of an approved treatment for COVID-19, in March the FDA began allowing researchers to request emergency authorization for the use of convalescent plasma which shows potential as a treatment for the disease.
Researchers at the UC College of Medicine are among those who joined the Mayo Clinic protocol for investigating convalescent plasma as a possible treatment for COVID-19. Convalescent plasma is obtained from people who have recovered from COVID-19 and have been free of symptoms for 28 days. This program may allow access to that plasma for hospitalized patients infected with the novel coronavirus who have severe or life-threatening COVID-19, or who may be at high risk for progression to severe or life-threatening disease.
This research garnered coverage from the Cincinnati Business Courier, Cincinnati Enquirer, WLWT, Fox19 and WVXU.
Featured image at top from freestocks on Unsplash.
Find the latest details related to coronavirus disease 2019 (covid-19) on the Centers for Disease Control and Prevention (CDC) website, and follow UC's latest information with regard to the virus.
Related Stories
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
University of Cincinnati graduate programs rise in national rankings across high-demand fields
May 13, 2026
University of Cincinnati graduate programs climbed in the latest U.S. News & World Report rankings, led by strong gains in workforce-focused fields including public health, clinical psychology and business.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.